조아제약
Financials
Valuation Metrics
조아제약's Market Cap is ₩170B. At end of 2025 it was ₩313B. Ranked #2370 of 2,436 in KR market (top 97%), #1589 of 1,649 on KOSDAQ (top 96%), #231 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 99%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 17.04B KRW | KR#2,370/2,436 Sec#231/234 |
| Revenue | 59.62B KRW | KR#1,687/2,436 Sec#113/234 |
| Net Income | -5.31B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 63.04B KRW | KR#2,055/2,436 Sec#177/234 |
| Net Assets | 21.62B KRW | KR#2,260/2,436 Sec#212/234 |
| Employees | 279 | KR#840/2,436 Sec#72/234 |
| Value | ||
| P/B | 0.79x | KR#1,264/2,436 Sec#74/234 |
| P/S | 0.29x | KR#569/2,436 Sec#12/234 |
| FCF Yield | -31.01% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -24.56% | KR#2,123/2,436 Sec#167/234 |
| ROA | -8.42% | KR#2,030/2,436 Sec#154/234 |
| Op. Margin | -9.41% | KR#1,965/2,436 Sec#134/234 |
| Revenue Growth | 2.15% | KR#1,306/2,436 Sec#120/234 |
| Financial Health | ||
| Debt Ratio | 291.59% | KR#2,119/2,436 Sec#218/234 |
| Total Debt | 24.97B KRW | KR#1,279/2,436 Sec#105/234 |
| FCF | -5.28B KRW | KR#1,513/2,436 Sec#119/234 |
| Cash | 2.83B KRW | KR#2,170/2,436 Sec#207/234 |
| Current Ratio | 1.08x | KR#1,726/2,436 Sec#176/234 |
| Performance | ||
| 1Y Return | -47.62% | KR#2,022/2,436 Sec#188/234 |
| 1M Return | -16.16% | KR#2,062/2,436 Sec#205/234 |
| From 52W High | -61.27% | KR#1,777/2,436 Sec#149/234 |
| 1Y MDD | -60.20% | KR#1,424/2,436 Sec#113/234 |
| Trading | ||
| Volume | 1,168,235 shares | KR#120/2,436 Sec#7/234 |
| Foreign Own. | 3.56% | KR#951/2,436 Sec#92/234 |
| Per Share | ||
| EPS | -153 KRW | KR—/2,436 Sec—/234 |
| BPS | 808 KRW | KR#2,328/2,436 Sec#212/234 |
Company Info
Joa Pharmaceutical, established in 1996, was formed following the acquisition of Samgang Pharmaceutical Company in 1988. It operates the pharmacy franchise Medipharm as a subsidiary. The company produces and supplies over 200 pharmaceuticals and health foods, including Hepatos and Evathion, supported by over 100 Medical Representatives across 15 nationwide sales offices. Since beginning exports to Vietnam in 1995, Joa Pharmaceutical now exports over 150 product types to 23 countries, striving to become a global healthcare leader through innovative product development and brand competitiveness. Joa Pharmaceutical is headquartered in Yeongdeungpo-gu, Seoul Metropolitan City.